Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers.
Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers.
复制标题
DOI：
10.3389/fonc.2012.00168
复制
发表时间：
2012
影响因子：
4.7
通讯作者：
Pyne NJ
中科院分区：
文献类型：
--
作者：
Pyne S;Edwards J;Ohotski J;Pyne NJ
有大量证据表明，生物活性脂质鞘氨醇1-磷酸（S1 P）、鞘氨醇激酶1（催化S1 P形成）和S1 P特异性G蛋白偶联受体在癌症中发挥作用。这一观点强调了最近的研究结果，表明鞘氨醇激酶1和S1 P受体是检测早期癌症和进展为侵袭性癌症的新的重要生物标志物。考虑S1 P代谢酶和S1 P受体的亚细胞分布及其与癌基因的空间功能相互作用对预后结果的影响。这些发现表明，S1 P除了是临床预后的生物标志物外，还可能是癌症干预的新治疗靶点。
There is substantial evidence for a role in cancer of the bioactive lipid sphingosine 1-phosphate (S1P), the enzyme sphingosine kinase 1 (that catalyses S1P formation) and S1P-specific G protein-coupled receptors. This perspective highlights recent findings demonstrating that sphingosine kinase 1 and S1P receptors are new important biomarkers for detection of early cancer and progression to aggressive cancer. The impact of the sub-cellular distribution of S1P metabolizing enzymes and S1P receptors and their spatial functional interaction with oncogenes is considered with respect to prognostic outcome. These findings suggest that S1P, in addition to being a biomarker of clinical prognosis, might also be a new therapeutic target for intervention in cancer.